Outcome of patients with primary glioblastoma in Chile: single centre series

Mariana Sinning, Michael Frelinghuysen, Marcela Gallegos, Andrés Cordova, Patricio Paredes, Conrado Vogel, Emi Sujima, Carlos Kamiya-Matsuoka, Felipe Valdivia, Mariana Sinning, Michael Frelinghuysen, Marcela Gallegos, Andrés Cordova, Patricio Paredes, Conrado Vogel, Emi Sujima, Carlos Kamiya-Matsuoka, Felipe Valdivia

Abstract

Background: Glioblastoma (GBM) is the most common and most aggressive primary malignant brain tumour. The standard of care is surgical resection, followed by radiotherapy with concurrent and adjuvant temozolomide. In Latin America, there is scarcity of information about the incidence of GBM and even less data regarding outcomes. In this study, we describe the clinicopathologic features, management and outcomes of GBM patients.

Methods: We describe a single-centre multidisciplinary team experience in managing GBM patients over an 11-year period (Jan 2005 to Dec 2016). Pathology was reviewed by the pathology collaborator and retrospective chart review performed for treatment and clinical outcomes.

Results: We identified 74 patients (50 males) with diagnosis of GBM. Median age at diagnosis was 58 years (range 24-79 years), and median Karnofsky performance status was 80%. Forty-three (58.1%) went to gross total resection, 20 (27%) partial resection and 11 (14.9%) biopsy. Sixty-four (87%) patients received Stupp regimen. The median overall survival (OS) was 13.9 months (standard error (SE) 1.71; 95% confidence interval (CI), 10.56-17.23). In patients treated according to Stupp regimen, the progression-free survival (PFS) was 10 months (SE 1.8; 95% CI, 6.481-13.519), the selfcare survival was 11.8 months (SE 1.61; 95% CI, 8.632-14.968) and the OS was 16.1 months (SE 1.53; 95% CI, 13.01-19.099).

Conclusions: This study reports the most complete analysis of epidemiology, clinical management and outcomes of patients with diagnosis of GBM in Chile treated with Stupp regimen. The PFS and OS are consistent with reports of US and Europe.

Keywords: Chile; Latin America; glioblastoma; glioma.

Conflict of interest statement

The authors have no conflicts of interest to declare.

© the authors; licensee ecancermedicalscience.

Figures

Figure 1.. Patients included in the study.
Figure 1.. Patients included in the study.
Figure 2.. Survival patients treated according to…
Figure 2.. Survival patients treated according to Stupp protocol.

References

    1. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10:459–466. doi: 10.1016/S1470-2045(09)70025-7.
    1. Miranda-Filho A, Piñeros M, Soerjomataram I, et al. Cancers of the brain and CNS: global patterns and trends in incidence. Neuro-Oncol. 2017;19:270–280.
    1. Primer informe de registros poblacionales de cancer de Chile Quinquenio 2003–2007. [8/15/20]. [ ]
    1. Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016;131:803–820. doi: 10.1007/s00401-016-1545-1.
    1. Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap) – A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42:377–381. doi: 10.1016/j.jbi.2008.08.010.
    1. Yang P, Wang Y, Peng X, et al. Management and survival rates in patients with glioma in China (2004-2010): a retrospective study from a single-institution. J Neurooncol. 2013;113:259–266. doi: 10.1007/s11060-013-1103-9.
    1. Salem A, Hashem SA, Al-Rashdan A, et al. The challenges of managing glioblastoma multiforme in developing countries: a trade-off between cost and quality of care. Haematol/Oncol Stem Cell Ther. 2011;4:116–120. doi: 10.5144/1658-3876.2011.116.
    1. Loureiro LV, Pontes LdeB, Callegharo-Filho D, et al. Initial care and outcome of glioblastoma multiforme patients in 2 diverse health care scenarios in Brazil: does public versus private health care matter? Neuro-Oncology. 2014;16:999–1005. doi: 10.1093/neuonc/not306.
    1. Ostrom QT, Gittleman H, Truitt G, et al. CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2011–2015. Neuro Oncol. 2018. pp. iv1–iv86.
    1. Sinha P, Kallogjeri D, Piccirillo JF. Assessment of comorbidities in surgical oncology outcomes. J Surg Oncol. 2014;110:629–635. doi: 10.1002/jso.23723.
    1. Hall WH, Jani AB, Ryu JK, et al. The impact of age and comorbidity on survival outcomes and treatment patterns in prostate cancer. Prostate Cancer Prostatic Dis. 2005;8:22–30. doi: 10.1038/sj.pcan.4500772.
    1. Moraes FY, Lo A, Morgan ER, et al. Management and outcomes in oldest-old population with glioblastoma. Can J Neurol Sci. 2018;45:199–205. doi: 10.1017/cjn.2017.278.
    1. Lorenzoni J, Torrico A, Villanueva P, et al. Surgery for high-grade gliomas in a developing country: survival estimation using a simple stratification system. Surg Neurol. 2008;70:591–597. doi: 10.1016/j.surneu.2007.08.004.
    1. Quezada C, Peigñan L, Segura R, et al. Study of resistance to chemotherapy mediated by ABC transporters in biopsies of glioblastoma multiforme. Rev Med Chile. 2011;139:415–424. doi: 10.4067/S0034-98872011000400001.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi